In patients with ADHD, MPH treatment decreases DAT availability [82,83,84,85], likely indicating altered baseline DAT levels in these patients [24,83], although this is not always observed [81]. The gene discussed is SLC6A3; the disease is attention deficit-hyperactivity disorder.